Most Read Articles
31 Jul 2016
New drug applications approved by US FDA as of 15 - 31 July 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Audrey Abella, 06 Jul 2017
The addition of aggressive local ablation to systemic therapy may extend overall survival (OS) in patients with unresectable colorectal cancer (CRC) with liver metastases compared with systemic therapy alone, according to a phase II trial.
06 Jul 2016
Access to primary care or insurance prior to diagnosis is associated with better outcomes in autoimmune hepatitis, according to a recent study.

Obesity ups risk of acute chronic liver failure in decompensated cirrhosis patients

26 Aug 2018
A higher than normal BMI is often a risk factor for many long-term health problems such as diabetes, hypertension, joint, heart and even liver problems.

In patients with decompensated cirrhosis, class III obesity increases the risk of acute on chronic liver failure (ACLF) development, a recent study has found.

Drawing from the United Network for Organ Sharing database, researchers identified 100,382 eligible participants, of whom 63,712 were nonobese (mean age 53.10±11.0 years; 62.9 percent male), 32,605 were class I–II obese (mean age 54.6±8.9 years; 63.8 percent male) and 4,065 were class III obese (mean age 52.6±9.1 years; 53.7 percent male).

At the time of liver transplantation, 7,630 patients had ACLF, of whom 4,688 were nonobese, 2,587 were class I–II obese and 355 were class III obese. Kaplan-Meier analysis revealed that those with class III obesity were significantly more likely to develop ACLF (p<0.001).

Multivariable Cox proportional hazards regression analysis further confirmed that class III obesity was a significant risk factor for ACLF (hazard ratio [HR], 1.24; 95 percent CI, 1.09–1.41; p<0.0001). The same was true for class I–II obesity (HR, 1.12; 1.05–1.19; p<0.001).

Other factors that significantly correlated with ACLF included older age, hepatitis C infection, ascites, alcoholic liver disease and hepatic encephalopathy.

Obesity was also associated with organ failure. While renal insufficiency was comparable between patient groups, renal failure was progressively more prevalent with increasing obesity class (p<0.001), and coagulation failure was most common in patients with class I–II obesity (51.3 percent). In contrast, liver failure as a component of ACLF was inversely correlated with obesity class.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 Jul 2016
New drug applications approved by US FDA as of 15 - 31 July 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Audrey Abella, 06 Jul 2017
The addition of aggressive local ablation to systemic therapy may extend overall survival (OS) in patients with unresectable colorectal cancer (CRC) with liver metastases compared with systemic therapy alone, according to a phase II trial.
06 Jul 2016
Access to primary care or insurance prior to diagnosis is associated with better outcomes in autoimmune hepatitis, according to a recent study.